

Management Of Castration Resistant Prostate Cancer Current Clinical Urology

Estramustine phosphate

Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer; *Clinical Genitourinary Cancer*. 13 (5): 441–446. doi:10.1016/j.clgc.2015

Estramustine phosphate (EMP), also known as estradiol normustine phosphate and sold under the brand names Emcyt and Estracyt, is a dual estrogen and chemotherapy medication which is used in the treatment of prostate cancer in men. It is taken multiple times a day by mouth or by injection into a vein.

Darolutamide was patented in 2011 and was approved for medical use in USA in July 2019, in the European Union in March 2020...

Prostate cancer

Eventually cancer cells can grow resistant to this treatment. This most-advanced stage of the disease, called castration-resistant prostate cancer, is treated

Prostate cancer is the uncontrolled growth of cells in the prostate, a gland in the male reproductive system below the bladder. Abnormal growth of the prostate tissue is usually detected through screening tests, typically blood tests that check for prostate-specific antigen (PSA) levels. Those with high levels of PSA in their blood are at increased risk for developing prostate cancer. Diagnosis requires a biopsy of the prostate. If cancer is present, the pathologist assigns a Gleason score; a higher score represents a more dangerous tumor. Medical imaging is performed to look for cancer that has spread outside the prostate. Based on the Gleason score, PSA levels, and imaging results, a cancer case is assigned a stage 1 to 4. A higher stage signifies a more advanced, more dangerous disease....

Oh is Director of Precision Medicine for Yale Cancer Center and Smilow Cancer Hospital. He is also Medical Director for the Cancer Service Line at Smilow Cancer Hospital in Greenwich. He previously served as Chief Medical Officer for the Prostate Cancer Foundation, the world's leading philanthropy for prostate cancer. He was also CMO of Sema4 (now known as GeneDx), a publicly traded genomics and health intelligence company. For 11 years, Oh was Chief of the Division of Hematology and Medical Oncology at The Mount Sinai Medical...

Side effects of EMP include nausea, vomiting, gynecomastia, feminization, demasculinization, sexual dysfunction, blood clots, and cardiovascular complications. EMP is a dual cytostatic and hence chemotherapeutic agent and a hormonal anticancer agent of the estrogen type. It is a prodrug of estramustine and estromustine in terms of its cytostatic effects and a prodrug of estradiol in relation to its estrogenic effects. EMP has strong estrogenic effects at typical clinical dosages, and consequently...

Relative to steroidal antiandrogens like cyproterone acetate and spironolactone, bicalutamide has better selectivity in its action, superior efficacy as an antagonist of the androgen receptor...

Side effects of apalutamide when added to castration include fatigue, nausea, abdominal pain, diarrhea, high blood pressure, rash, falls, bone fractures, and an underactive thyroid. Rarely, it can cause seizures. The medication has a high potential for drug interactions. Apalutamide is an antiandrogen, and acts as an antagonist of the androgen receptor, the biological target of androgens like testosterone and dihydrotestosterone. In doing so, it prevents the effects of these hormones in the prostate gland and elsewhere in the body.

Bicalutamide

castration resistant prostate cancer: resistance mechanisms and emerging treatment strategies; *American Journal of Clinical and Experimental Urology*

Bicalutamide, sold under the brand name Casodex among others, is an antiandrogen medication that is primarily used to treat prostate cancer. It is typically used together with a gonadotropin-releasing hormone (GnRH) analogue or surgical removal of the testicles to treat metastatic prostate cancer (mPC). To a lesser extent, it is used at high doses for locally advanced prostate cancer (LAPC) as a monotherapy without castration. Bicalutamide was also previously used as monotherapy to treat localized prostate cancer (LPC), but authorization for this use was withdrawn following unfavorable trial findings. Besides prostate cancer, bicalutamide is limitedly used in the treatment of excessive hair growth and scalp hair loss in women, as a puberty blocker and component of feminizing hormone

therapy...

William K. Oh

investigator on multiple clinical trials of chemotherapy in castration-resistant (CRPC) prostate cancer and for three trials of neoadjuvant chemotherapy

William K. Oh, is an American medical oncologist, academic leader and expert in the management of prostate cancer. He has also held leadership roles in industry and non-profits, including as Chair of the American Cancer Society's National Prostate Cancer Roundtable.

Darolutamide

treatment of non-metastatic castration-resistant prostate cancer in men. It is specifically approved to treat non-metastatic castration-resistant prostate cancer

Darolutamide, sold under the brand name Nubeqa, is an antiandrogen medication which is used in the treatment of non-metastatic castration-resistant prostate cancer in men. It is specifically approved to treat non-metastatic castration-resistant prostate cancer (nmCRPC) in conjunction with surgical or medical castration. The medication is taken by mouth twice per day with food.

Abiraterone acetate

used to treat prostate cancer. Specifically it is used together with a corticosteroid for metastatic castration-resistant prostate cancer (mCRPC) and metastatic

Abiraterone acetate, sold under the brand name Zytiga among others, is a medication used to treat prostate cancer. Specifically it is used together with a corticosteroid for metastatic castration-resistant prostate cancer (mCRPC) and metastatic high-risk castration-sensitive prostate cancer (mCSPC). It should either be used following removal of the testicles or along with a gonadotropin-releasing hormone (GnRH) analog. It is taken by mouth.

Enzalutamide

treatment of prostate cancer. It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC)

Enzalutamide, sold under the brand name Xtandi, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is indicated for use in conjunction with castration in the treatment of metastatic castration-resistant prostate cancer (mCRPC), nonmetastatic castration-resistant prostate cancer, and metastatic castration-sensitive prostate cancer (mCSPC). It is taken by mouth.

Management of prostate cancer

2008). "Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains

Treatment for prostate cancer may involve active surveillance, surgery, radiation therapy – including brachytherapy (prostate brachytherapy) and external-beam radiation therapy, proton therapy, high-intensity focused ultrasound (HIFU), cryosurgery, hormonal therapy, chemotherapy, or some combination. Treatments also extend to survivorship based interventions. These interventions are focused on five domains including: physical symptoms, psychological symptoms, surveillance, health promotion and care coordination. However, a published review has found only high levels of evidence for interventions that target physical and psychological symptom management and health promotion, with no reviews of interventions for either care coordination or surveillance. The favored treatment option depends on...

Apalutamide

metastatic castration-sensitive prostate cancer and the treatment of people with non-metastatic castration-resistant prostate cancer. Apalutamide is used in conjunction

Apalutamide, sold under the brand name Erleada among others, is a nonsteroidal antiandrogen (NSAA) medication used for the treatment of prostate cancer. It is an androgen receptor inhibitor. It is taken by mouth.

Apalutamide was first described in 2007, and was approved...

Side effects of enzalutamide when added to castration include asthenia, back pain, diarrhea, arthralgia, and hot flashes. Rarely, it can cause seizures. It has a high potential for drug interactions. Enzalutamide is an antiandrogen, and acts as an antagonist of the androgen receptor, the biological target of androgens like testosterone and dihydrotestosterone. In doing so, it prevents...

Common side effects include tiredness, vomiting, headache, joint pain, high blood pressure, swelling, low blood potassium, high blood sugar, hot flashes, diarrhea, and cough. Other severe side effects may include liver failure and adrenocortical insufficiency. In males whose partners can become pregnant, birth control is recommended. Supplied as abiraterone...

Comparison of bicalutamide with other antiandrogens

shows slightly inferior effectiveness in the treatment of prostate cancer compared to castration and GnRH analogues but a different and potentially superior

Comparison of the nonsteroidal antiandrogen (NSAA) bicalutamide with other antiandrogens reveals differences between the medications in terms of efficacy, tolerability, safety, and other parameters. Relative to the other first-generation NSAs, flutamide and nilutamide, bicalutamide shows improved potency, efficacy, tolerability, and safety, and has largely replaced these medications in clinical practice. Compared to the second-generation NSAs, enzalutamide and apalutamide, bicalutamide has inferior potency and efficacy but similar tolerability and safety and a lower propensity for drug interactions.

Side effects of darolutamide added to castration may include fatigue, asthenia, pain in the arms and legs, and rash. Darolutamide is a nonsteroidal antiandrogen (NSAA), and acts as a selective antagonist of the androgen receptor (AR). It has been referred to as a second- or third-generation NSAA.

https://www.topperlearning.motion.ac.in/trusumbluj/2FH3485/gpiope/4FH2418930/carrahers_polymer_chemistry_ninth-edition_by-carraher-jr-charles_e_crc_press_2013_9th_edition_hardcover_hardcover.pdf

https://www.topperlearning.motion.ac.in/munitul/9U6B627/uintitlig/1U5B756365/suzuki-dl650_dl_650_2005_repair_service_manual.pdf

https://www.topperlearning.motion.ac.in/jconstryctn/7B6769M/crasnl/1B4210M133/khanyisa_nursing-courses.pdf

https://www.topperlearning.motion.ac.in/wrusumblux/855I66A/bistablishy/943I8621A8/craftsman_chainsaw_20_inch-46cc-manual.pdf

https://www.topperlearning.motion.ac.in/lguarantuup/T72K605/tintitlik/T57K797753/market-leader-upper_intermediate-key_answers.pdf

https://www.topperlearning.motion.ac.in/uinjuruk/57324YD/lnasdd/1201080DY1/outsourcing_as_a_strategic_management_decision_springer.pdf

https://www.topperlearning.motion.ac.in/ksogndn/6BY0900/sconseastq/8BY5689934/beta_r125-minicross_factory-service-repair-manual.pdf

https://www.topperlearning.motion.ac.in/vtustw/56Q04Z1/oclassufya/73Q10Z6309/CCR1016-12g_manual.pdf

https://www.topperlearning.motion.ac.in/mpruparuu/43612WW/hadvocativ/796635W70W/mitsubishi_montero_workshop_repair_manual_download_1996_1997.pdf

https://www.topperlearning.motion.ac.in/ncovurd/E88704Q/uilictv/E164094Q18/panasonic_stereo-user_manual.pdf